XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Collaborations - Additional Information (Details)
$ / shares in Units, € in Millions
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jan. 18, 2021
USD ($)
$ / shares
shares
Aug. 31, 2018
USD ($)
Mar. 14, 2018
EUR (€)
Jan. 23, 2017
USD ($)
Jan. 31, 2022
Jan. 31, 2018
USD ($)
PerformanceObligation
Antibody
Milestone
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Feb. 12, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Development milestones achieved             $ 2,500,000        
Lilly Collaborations Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Non-refundable upfront payment receivable $ 40,000,000                    
Issuance of common stock, shares | shares 706,834                    
Common stock stated purchase price per share | $ / shares $ 28.295                    
Proceeds from issuance of common stock, net $ 20,000,000                    
Fixed consideration 43,500,000                   $ 43.5
Fee incurred for extension of research term                   $ 500,000  
Increase in transaction price                   $ 500,000  
Upfront payment 40,000,000                    
Net fair value of shares $ 16,500,000                    
Incyte Collaboration and License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Development milestones achieved             1,000,000   $ 6,000,000    
Incyte Collaboration and License Agreement | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Residual royalty percentage         4.00%            
Incyte Collaboration and License Agreement | License and Related Activities                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Collaborations, transaction price as deferred revenue       $ 152,600,000              
Second ONO Research and License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Non-refundable upfront payment receivable | €     € 0.7                
Payment to compensate research services | €     0.3                
Over time payment for full time equivalent funding | €     € 0.2                
Development milestones achieved             $ 0 $ 0      
Simcere Collaboration and License Agreement                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of bispecific antibodies under collaboration and license agreement | Antibody           3          
Non-refundable upfront payment received           $ 2,750,000          
Collaborations, transaction price as revenue           $ 2,750,000          
Milestone payments received   $ 1,800,000                  
Number of milestones achieved | Milestone           3          
Simcere Collaboration and License Agreement | License and Performance | Research and Development                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Number of performance obligation | PerformanceObligation           3